AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26649536 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week Internet-delivered acceptance-based cognitive behavioral therapy (ACT)
Number of subjects: 0
Study 26649536 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 23832310 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic nasobiliary drainage (ENBD)
Number of subjects: 94
Study 23832310 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic retrograde biliary drainage (ERBD)
Number of subjects: 94
Study 21111590 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term nocturnal non-invasive ventilation (NIV)
Number of subjects: 26
Study 21111590 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of NIV
Number of subjects: 26
Study 19379147 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hypoglycemic agents (OHAs)
Number of subjects: 102
Study 19379147 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy
Number of subjects: 102
Study 19379147 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglitinides
Number of subjects: 102
Study 19379147 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemic patients
Number of subjects: 102
Study 19379147 — intervention group
Group type: COMPARATOR
Intervention: Non-hypoglycemic patients
Number of subjects: 102
Study 17971948 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbs treatment, administered as customized soups, taken twice daily for one week.
Number of subjects: 0
Study 17971948 — intervention group
Group type: COMPARATOR
Intervention: Western medicine treatment (WM), details not specified.
Number of subjects: 0
Study 15233285 — intervention group
Group type: EXPERIMENTAL
Intervention: 201Tl scintigraphy
Number of subjects: 30
Study 15233285 — intervention group
Group type: COMPARATOR
Intervention: Three-phase bone scintigraphy
Number of subjects: 30
Study 10996353 — intervention group
Group type: EXPERIMENTAL
Intervention: C242T polymorphism of the p22 phox gene
Number of subjects: 324
Study 10996353 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects without known arterial disease)
Number of subjects: 324
Study 9497572 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 immunostaining in adenomas
Number of subjects: 72
Study 9497572 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 immunostaining in carcinomas
Number of subjects: 72
Study 9497572 — intervention group
Group type: COMPARATOR
Intervention: Survival analysis based on p53 expression in cancer patients
Number of subjects: 72
Study 8371026 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 64570
Study 8371026 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination (4 or more scars)
Number of subjects: 64570
Study 3092655 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms administered twenty minutes before each dose of aspirin
Number of subjects: 0
Study 3092655 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 600 mg given over 48 hours
Number of subjects: 0
Study 31541565 — intervention group
Group type: COMPARATOR
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 0
Study 31541565 — intervention group
Group type: EXPERIMENTAL
Intervention: Stromal vascular fraction-enriched platelet-rich plasma (SVF-PRP)
Number of subjects: 0
Study 29324578 — intervention group
Group type: COMPARATOR
Intervention: 3× per week (n = 16)
Number of subjects: 28
Study 29324578 — intervention group
Group type: EXPERIMENTAL
Intervention: 6× per week (n = 12)
Number of subjects: 28
Study 27391533 — intervention group
Group type: EXPERIMENTAL
Intervention: BioTrue (MPS)
Number of subjects: 253
Study 27391533 — intervention group
Group type: COMPARATOR
Intervention: Clear Care (hydrogen peroxide control)
Number of subjects: 253
Study 27391533 — intervention group
Group type: EXPERIMENTAL
Intervention: Senofilcon A
Number of subjects: 253
Study 27391533 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B
Number of subjects: 253
Study 27391533 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfilcon A
Number of subjects: 253
Study 27391533 — intervention group
Group type: EXPERIMENTAL
Intervention: Other SCL types
Number of subjects: 253
Study 24816942 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-potentiated startle in individuals with FXS
Number of subjects: 3
Study 24816942 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-potentiated startle in individuals with DD
Number of subjects: 3
Study 24816942 — intervention group
Group type: COMPARATOR
Intervention: Emotion-potentiated startle in typically developing controls
Number of subjects: 3
Study 24816942 — intervention group
Group type: EXPERIMENTAL
Intervention: Social avoidance in individuals with FXS
Number of subjects: 3
Study 22210576 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg daily)
Number of subjects: 4900
Study 22210576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4900
Study 20136179 — intervention group
Group type: EXPERIMENTAL
Intervention: Consonant-oriented training group
Number of subjects: 2
Study 20136179 — intervention group
Group type: COMPARATOR
Intervention: Vowel-oriented training group
Number of subjects: 2
Study 18757653 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Monthly replacement of the ring with no ring-free days
Number of subjects: 65
Study 18757653 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Monthly replacement of the ring with a 4-day hormone-free interval if breakthrough bleeding/spotting occurred for 5 days or more
Number of subjects: 65
Study 18757653 — intervention group
Group type: COMPARATOR
Intervention: 4-day hormone-free interval
Number of subjects: 65
Study 15530590 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined breast health/weight loss intervention
Number of subjects: 64
Study 15530590 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined breast health/weight loss intervention (Cohort 2)
Number of subjects: 64
Study 12911203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cato 0.51 x min(‐1) without HME (group 1)
Number of subjects: 48
Study 12911203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cato 1.01 x min(‐1) without HME (group 2)
Number of subjects: 48
Study 12911203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cato 0.51 x min(‐1) with HME (group 3)
Number of subjects: 48
Study 12911203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cato 1.01 x min(‐1) with HME (group 4)
Number of subjects: 48
Study 12911203 — intervention group
Group type: COMPARATOR
Intervention: Aestiva 0.51 x min(‐1) without HME (group 5)
Number of subjects: 48
Study 12911203 — intervention group
Group type: COMPARATOR
Intervention: Aestiva 1.01 x min(‐1) without HME (group 6)
Number of subjects: 48
Study 12911203 — intervention group
Group type: EXPERIMENTAL
Intervention: Aestiva 0.51 x min(‐1) with HME (group 7)
Number of subjects: 48
Study 12911203 — intervention group
Group type: EXPERIMENTAL
Intervention: Aestiva 1.01 x min(‐1) with HME (group 8)
Number of subjects: 48
Study 10440160 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged heparin infusion (12 to 24 h) followed by sheath removal (Group 1)
Number of subjects: 414
Study 10440160 — intervention group
Group type: EXPERIMENTAL
Intervention: Early removal of sheaths followed by reinstitution of heparin infusion for 12 to 18 h (Group 2)
Number of subjects: 414
Study 10440160 — intervention group
Group type: COMPARATOR
Intervention: No further heparin after intervention with early sheath removal (Group 3)
Number of subjects: 414
Study 10440160 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 414
Study 7759460 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol powder 200 micrograms
Number of subjects: 46
Study 7759460 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol aerosol 180 micrograms
Number of subjects: 46
Study 7759460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 2334618 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous i.v. infusion of morphine (mean 73.6 mg)
Number of subjects: 10
Study 2334618 — intervention group
Group type: COMPARATOR
Intervention: Continuous extradural infusion of 0.25% bupivacaine (mean 192 mg)
Number of subjects: 10
Study 7458119 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ampicillin in vaginal hysterectomies
Number of subjects: 100
Study 7458119 — intervention group
Group type: COMPARATOR
Intervention: Control group in abdominal hysterectomies
Number of subjects: 100
Study 30538032 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficiency-based laparoscopic skills training
Number of subjects: 38
Study 29103841 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossflow pump
Number of subjects: 5
Study 29103841 — intervention group
Group type: EXPERIMENTAL
Intervention: 24K pump
Number of subjects: 5
Study 29103841 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Wave III pump
Number of subjects: 5
Study 29103841 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Pump RF
Number of subjects: 5
Study 29103841 — intervention group
Group type: EXPERIMENTAL
Intervention: FMS/DUO+
Number of subjects: 5
Study 26870683 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA-enriched white rice (11.2 mg GABA/100 g of rice)
Number of subjects: 39
Study 26870683 — intervention group
Group type: COMPARATOR
Intervention: Placebo rice (2.7 mg GABA/100 g of rice)
Number of subjects: 39
Study 25033925 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU Vitamin D3 at monthly intervals
Number of subjects: 300
Study 25033925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 21577132 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol 400 at 3 mL/s (IDR = 1.2 gI/s)
Number of subjects: 100
Study 21577132 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol 400 at 4 mL/s (IDR = 1.6 gI/s)
Number of subjects: 100
Study 21577132 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol 300 at 5.4 mL/s (IDR = 1.6 gI/s)
Number of subjects: 100
Study 21577132 — intervention group
Group type: COMPARATOR
Intervention: Iomeprol 300 at 4 mL/s (IDR = 1.2 gI/s)
Number of subjects: 100
Study 20399996 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible tablet formulation of ampicillin/probenecid (1500 mg total; 250 mg each containing ampicillin 194.5 mg and probenecid 55.5 mg)
Number of subjects: 20
Study 20399996 — intervention group
Group type: COMPARATOR
Intervention: Branded capsule formulation of ampicillin/probenecid (1500 mg total; 250 mg each containing ampicillin 194.5 mg and probenecid 55.5 mg)
Number of subjects: 20
Study 20399996 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 20
Study 18061070 — intervention group
Group type: EXPERIMENTAL
Intervention: GTN treatment for 48 hours
Number of subjects: 50
Study 18061070 — intervention group
Group type: COMPARATOR
Intervention: Control (nontolerant vessels)
Number of subjects: 50
Study 18061070 — intervention group
Group type: COMPARATOR
Intervention: Incubation of control venous vessels with GTN
Number of subjects: 50
Study 15683530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse duration of 0.2 ms
Number of subjects: 20
Study 15683530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse duration of 1.0 ms
Number of subjects: 20
Study 15683530 — intervention group
Group type: COMPARATOR
Intervention: Pulse duration of 0.2 ms vs 1.0 ms
Number of subjects: 20
Study 11889152 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 3
Study 11889152 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 3
Study 11889152 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 3
Study 9806691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular triamcinolone acetonide 10 mg in isotonic saline 20 mL
Number of subjects: 60
Study 9806691 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline 20 mL
Number of subjects: 60
Study 7696069 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled extradural analgesia (PCEA)
Number of subjects: 40
Study 7696069 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled i.v. analgesia (PCIVA)
Number of subjects: 40
Study 2654207 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol 0.25%
Number of subjects: 0
Study 2654207 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol 0.50%
Number of subjects: 0
Study 2654207 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol 0.75%
Number of subjects: 0
Study 2654207 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol 1.0%
Number of subjects: 0
Study 2654207 — intervention group
Group type: COMPARATOR
Intervention: Polidocanol 0.25%, 0.50%, 0.75%, 1.0%
Number of subjects: 0
Study 337493 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg
Number of subjects: 0
Study 337493 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 1.0 mg/kg
Number of subjects: 0
Study 337493 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (larger doses)
Number of subjects: 0
Study 6797733 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerine
Number of subjects: 31
Study 6797733 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 31
Study 30782672 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Metacognitive Grief Therapy (MCGT)
Number of subjects: 22
Study 30782672 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 22
Study 29522530 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Clinic Day (FCD) intervention
Number of subjects: 2679
Study 29522530 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2679
Study 27394187 — intervention group
Group type: EXPERIMENTAL
Intervention: Massive cerebrospinal fluid (CSF) replacement (CR group)
Number of subjects: 87
Study 27394187 — intervention group
Group type: COMPARATOR
Intervention: Regular therapy alone (C group)
Number of subjects: 87
Study 27394187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 87
Study 24553103 — intervention group
Group type: EXPERIMENTAL
Intervention: Paretic‐No Mirror
Number of subjects: 93
Study 24553103 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparetic‐Mirror
Number of subjects: 93
Study 24553103 — intervention group
Group type: COMPARATOR
Intervention: Nonparetic‐No Mirror
Number of subjects: 93
Study 24553103 — intervention group
Group type: COMPARATOR
Intervention: Bilateral‐Screen
Number of subjects: 93
Study 24553103 — intervention group
Group type: COMPARATOR
Intervention: Bilateral‐Mirror
Number of subjects: 93
Study 22916192 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-7 vaccine
Number of subjects: 200
Study 22916192 — intervention group
Group type: COMPARATOR
Intervention: Serogroup C meningococcal conjugate vaccine
Number of subjects: 200
Study 20466791 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed choice invitation
Number of subjects: 1272
Study 20466791 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation
Number of subjects: 1272
Study 17545497 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-maker perspective
Number of subjects: 2400
Study 17545497 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure to make a decision
Number of subjects: 2400
Study 15846268 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 125
Study 15846268 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 125
Study 12063103 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient responses to HRQOL measures
Number of subjects: 0
Study 12063103 — intervention group
Group type: COMPARATOR
Intervention: Proxy responses to HRQOL measures
Number of subjects: 0
Study 9707054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 20
Study 9707054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg b.i.d.
Number of subjects: 20
Study 9707054 — intervention group
Group type: COMPARATOR
Intervention: Control (no ranitidine)
Number of subjects: 20
Study 7497050 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype esophageal detection device (EDD)
Number of subjects: 51
Study 2122630 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine 10 mg/kg (n = 6)
Number of subjects: 12
Study 2122630 — intervention group
Group type: COMPARATOR
Intervention: Saline (n = 6)
Number of subjects: 12
Study 366182 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg intravenous indomethacin
Number of subjects: 47
Study 366182 — intervention group
Group type: COMPARATOR
Intervention: 5 mg intravenous riboflavin (placebo)
Number of subjects: 47
Study 31627177 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg twice daily)
Number of subjects: 49
Study 31627177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 29902418 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50
Study 29902418 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 50
Study 26566950 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple telephone reminder (TEL)
Number of subjects: 856
Study 26566950 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone support (TEL-SUPP)
Number of subjects: 856
Study 26566950 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone support plus anticipated regret (TEL-SUPP-AR)
Number of subjects: 856
Study 26566950 — intervention group
Group type: COMPARATOR
Intervention: No telephone call (control)
Number of subjects: 856
Study 26566950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention participants (per protocol analysis)
Number of subjects: 856
Study 24341324 — intervention group
Group type: EXPERIMENTAL
Intervention: TPVB plus IV PCA
Number of subjects: 34
Study 24341324 — intervention group
Group type: COMPARATOR
Intervention: IV PCA alone
Number of subjects: 34
Study 23312888 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus paclitaxel (10 mg/kg on days 1 and 15; 90 mg/m² on days 1, 8, and 15, every 4 weeks)
Number of subjects: 564
Study 23312888 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus paclitaxel
Number of subjects: 564
Study 23312888 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus capecitabine (15 mg/kg on day 1; 1000 mg/m² twice daily on days 1-14, every 3 weeks)
Number of subjects: 564
Study 23312888 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus capecitabine
Number of subjects: 564
Study 20216027 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided regional anesthesia (UGRA)
Number of subjects: 500
Study 20216027 — intervention group
Group type: COMPARATOR
Intervention: Standard nerve localization tools
Number of subjects: 500
Study 18816591 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative muscle testing (QMT)
Number of subjects: 0
Study 18816591 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional activities assessment (FAA)
Number of subjects: 0
Study 18816591 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 0
Study 18816591 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function testing (PFT)
Number of subjects: 0
Study 15722700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive telephone follow-up (12 weekly phone calls)
Number of subjects: 507
Study 15722700 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard disease management program without intensive telephone follow-up)
Number of subjects: 507
Study 12823593 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 microg/kg peginterferon‐alpha‐2b twice weekly for 4 weeks
Number of subjects: 10
Study 12823593 — intervention group
Group type: COMPARATOR
Intervention: 1.0 microg/kg peginterferon‐alpha‐2b once weekly for 4 weeks
Number of subjects: 10
Study 10910848 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (4 mg)
Number of subjects: 60
Study 10910848 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol (0.625 mg)
Number of subjects: 60
Study 10910848 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 9013368 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 455
Study 9013368 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen
Number of subjects: 455
Study 9013368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study 8237746 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (12,500 units subcutaneously every 12 hours for three doses after sheath removal)
Number of subjects: 151
Study 8237746 — intervention group
Group type: COMPARATOR
Intervention: Intravenous heparin (1000 units/hour for 12 to 18 hours)
Number of subjects: 151
Study 3548987 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 38
Study 3548987 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 38
Study 28488924 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 10
Study 27149489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus before sedation, continuous infusion at 2 mg/kg/h during sedation)
Number of subjects: 66
Study 27149489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 66
Study 27149489 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline, same bolus and infusion volumes as lidocaine)
Number of subjects: 66
Study 25304475 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous right thoracic paravertebral block with 10-mL bolus of 0.2% ropivacaine followed by continuous infusion of 6 mL/h for 24 hours (PVB group)
Number of subjects: 48
Study 25304475 — intervention group
Group type: COMPARATOR
Intervention: Saline administered through the same catheter scheme (control group)
Number of subjects: 48
Study 25304475 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous right thoracic paravertebral block (PVB group)
Number of subjects: 48
Study 25304475 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 48
Study 22860302 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1 mg x kg(‐1) on induction)
Number of subjects: 13
Study 22860302 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (5% inspired concentration)
Number of subjects: 13
Study 22860302 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 13